From the beginning, J & J was an advocate of antiseptic surgical procedures. This policy coincided with a move into pharmaceuticals, hygiene products, and textiles. The first international affiliate was founded in Canada in 1919. Johnson's immediate successor was Philip Hofmann, who, much like the General, had started as a shipping clerk and worked his way up the ladder. In 1943 Johnson wrote a credo outlining the company's four areas of social responsibility: first to its customers; second to its employees; third to the community and environment; and fourth to the stockholders. These acquisitions will allow McNeil  and McNeil Canada to enhance their positions in the United States and Canada, respectively, in the important digestive health category. In 1989 Bristol-Myers launched an aggressive advertising campaign that positioned its Nuprin brand ibuprofen pain reliever in direct competition with Tylenol. To bolster its drug R & D efforts, J & J completed its first major pharmaceutical deal since the 1961 purchase of Janssen Pharmaceutica. Johnson joined forces with his brothers, James Wood Johnson and Edward Mead Johnson, and the three began producing dressings in 1886 in New Brunswick, New Jersey, with 14 employees in a former wallpaper factory. In 2019, JNJ stock’s 12% return has lagged the S&P’s 27% return by a wide margin. The first introduced Carefree and Stayfree sanitary napkins into a market that was dominated by the acknowledged feminine products leader, Kimberly-Clark. At the same time, Burke did not turn his back on the company's position as a leader in professional healthcare products. Before 2010, the company had an infrequent number of recalls and lawsuits related to its products and business practices. These statements are based on current expectations of future events. Advertising was canceled immediately, and J & J recalled all Tylenol products from store shelves. One of the first product lines developed by this venture was the Mylanta brand of gastrointestinal products. Described as dynamic and restless with a keen sense of duty, Johnson had attained the rank of brigadier general in World War II and served as vice-chairman of the War Production Board. J & J had been a pioneer in the market for coronary stents, devices used to keep arteries open following angioplasty, but its stent sales fell from $700 million in 1996 to just over $200 million in 1998 after competitors introduced second-generation stents and J & J did not. Call 1-800-755-4008 (English) or 1-888-466-8746 (Spanish) or click here for Customer Service. New York Times. Available for Android and iOS devices. 1975: Through a significant price decrease, Tylenol is transformed into a mass-marketed product. Plus, I expect the company to continue to experience litigation expenses at its average rate going forward. Accessed Sept. 15, 2020. Although he remained active in the business, chairmanship of the company went outside the family for the first time. This page contains corporate information for pharmaceutical companies marketing products in the United States. Pharmaceutical stocks, as represented by the iShares U.S. Pharmaceuticals ETF (IHE), have performed on par with the broader market over the past year. Net earnings had nearly quadrupled since 1989, while net sales nearly tripled over the same period. Supernus Pharmaceuticals Inc. "Supernus Completes Acquisition of CNS Portfolio from US WorldMeds." BENADRYL ALLERGY. The percentage of deaths due to infections following surgery was quite high and hospitals were eager to find a solution. Principal Subsidiaries: Advanced Sterilization Products; Centocor; Cordis Corporation; DePuy; Ethicon, Inc.; Ethicon Endo-Surgery, Inc.; Independence Technology; Indigo Medical, Inc.; Janssen Pharmaceutica Inc.; Johnson & Johnson Consumer Products, Inc.; Johnson & Johnson Development Corporation; Johnson & Johnson Health Care Systems Inc.; Johnson & Johnson Medical; Johnson & Johnson-Merck Consumer Pharmaceuticals Co. (50%); Johnson & Johnson Sales and Logistics Company; Johnson & Johnson Vision Care, Inc.; LifeScan, Inc.; McNeil Consumer Healthcare; McNeil Specialty Products Company; Neutrogena Corporation; Noramco, Inc.; Ortho Biotech Inc.; Ortho-Clinical Diagnostics, Inc.; Ortho Dermatological; Ortho-McNeil Pharmaceutical, Inc.; Personal Products Company; R.W.